KRAS and colorectal carcinoma: 39% of patients positive for a KRAS mutation in cfDNA had a KRAS mutant colorectal neoplasia (111), suggesting to add cfDNA testing for frequent CRC mutations in screening programmes despite restriction to well-known CRC genetic aberrations.